Clinical trials: Hepatic Encephalopathy (HE)
Liver Cirrhosis
Embolization of Large Spontaneous Portosystemic Shunts for the Prevention of Post-TIPS Hepatic Encephalopathy
The purpose of this study is to determine whether transjugular intrahepatic portosystemic shunt (TIPS) combined with large spontaneous portosystemic shunts embolization are effective in the prevention of hepatic encephalopathy…
- Trial name
- NCT02156232
- Testing
- TIPS, SPSS embolization
- Where
- China
- Volunteers
- 56 people
- Sponsor
- Air Force Military Medical University, China
Hepatic Cirrhosis, Hepatic Encephalopathy (HE)
MNK6106 for Liver Disease (Hepatic Cirrhosis) That in the Past Has Affected the Brain (Hepatic Encephalopathy)
The main reason for this study is to see how the study drug interacts with the body. It will compare different doses of the study drug with a drug already in use.
- Trial name
- NCT03712280
- Testing
- MNK6106, Rifaximin
- Where
- 5 sites in United States, Puerto Rico
- Volunteers
- 50 people
- Sponsor
- Mallinckrodt
Cirrhoses, Liver, Hepatic Encephalopathy (HE)
Study on Proteomic and Microbiome Changes in Patients With Hepatic Encephalopathy (HE)
The objective of this observational study is to compare the differences in proteomics and gut microbiome between the liver cirrhosis group without hepatic encephalopathy and the hepatic encephalopathy group through proteomics and…
- Trial name
- NCT07150195
- Where
- China
- Volunteers
- 32 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Hepatic Encephalopathy
S. Endotoxin, Inflammatory Mediators and MRS Before and After Treatment in MHE
The purpose of this study is to examine S.endotoxins , inflammatory mediators and Magnetic Resonance Spectroscopy (MRS) before and after treatment in patients of cirrhosis and minimal hepatic encephalopathy.
- Trial name
- endtxninHE (NCT01446523)
- Testing
- Lactulose
- Where
- India
- Volunteers
- 60 people
- Sponsor
- Govind Ballabh Pant Hospital
Hepatic Encephalopathy, Decompensated Cirrhosis
BCAA vs. Rifaximin in Patients With Cirrhosis for Secondary Prophylaxis of HE
Rationale Patients who recover from an episode of overt HE(OHE) are at risk of recurrent episodes of HE and persistent minimal hepatic encephalopathy, impacting their daily functioning and mental health.
- Conditions
- Hepatic Encephalopathy, Decompensated Cirrhosis, Minimal Hepatic Encephalopathy
- Trial name
- HERB (NCT06538077)
- Testing
- Oral Branched chain Amino acid, Rifaximin 550 MG, Lactulose
- Where
- India
- Volunteers
- 336 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Liver Cirrhosis, Variceal Bleeding, Cirrhosis
Underdilated-stent Technique Improves Post-TIPS Encephalopathy
Transjugular intrahepatic portosystemic shunt (TIPS) is a critical therapeutic approach for managing esophagogastric variceal bleeding and refractory ascites in decompensated cirrhosis patients.
- Conditions
- Liver Cirrhosis, Variceal Bleeding, Cirrhosis, Ascites Hepatic, Hepatic Encephalopathy (HE)
- Trial name
- NCT07349654
- Testing
- 6mm balloon dilation, 8mm balloon dilation
- Where
- 2 sites in China
- Volunteers
- 72 people
- Sponsor
- The Second Affiliated Hospital of Chongqing Medical University
Hepatic Encephalopathy, Cirrhosis
Metobolomics in the Characterisation of HE
Hepatic encephalopathy is (HE) defined by the neurological and/or neuropsychological symptoms caused by an acute or chronic liver disease and/or a portosystemic shunt.
- Trial name
- METABO-EH (NCT06245473)
- Testing
- blood sample
- Where
- 2 sites in France
- Volunteers
- 1 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Liver Cirrhosis, Hepatic Encephalopathy
Cerebral Oxygen, Blood Flow and Ammonia Uptake in Patients With Cirrhosis and an Acute Episode of Hepatic Encephalopathy (HE)
We wish to study patients with liver cirrhosis during and 2 weeks after an acute episode of liver coma (hepatic encephalopathy).
- Trial name
- NCT01151475
- Where
- Denmark
- Volunteers
- 10 people
- Sponsor
- University of Aarhus
Hepatic Encephalopathy, Cirrhosis
Microbiota trAnSplant ThERaPy In hEpatiC Encephalopathy (MASTERPIECE)
The goal of this clinical trial is to find out whether changing the microbes in the bowels of Veterans with cirrhosis and hepatic encephalopathy (a condition that affects the brain as a result of liver problems) using capsules…
- Trial name
- MASTERPIECE (NCT07528690)
- Testing
- Microbiota transplant therapy (MTT) capsules
- Where
- 3 sites in United States
- Volunteers
- 162 people
- Sponsor
- VA Office of Research and Development
Acute on Chronic Liver Failure (ACLF), Hepatic Encephalopathy (HE)
RENEW: Study of Porcine Liver Support in Participants With Acute-on-Chronic Liver Failure
This is a Phase 1/2, first-in-human (FIH) safety, proof-of-concept, two-part study of the genetically-engineered EGEN-5784 liver in combination with the metra® extra-corporeal liver cross-circulation (ELC) system in participants…
- Trial name
- NCT07429838
- Testing
- metra® Extracorporeal Liver Cross-Circulation (ELC) system (OrganOx), EGEN-5784 (genetically engineered porcine liver)
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- eGenesis, INC
Acute-On-Chronic Liver Failure, Hepatic Encephalopathy
Early Postoperative CRRT After Liver Transplantation in ACLF Patients With Overt HE
Pretransplant hepatoencephalopathy (HE) markedly impacts recipient outcomes after liver transplantation. Intraoperative CRRT showed benefits but feasibility was much concerned.
- Trial name
- LTeCRRT (NCT04317222)
- Testing
- eCRRT
- Volunteers
- 250 people
- Sponsor
- Third Affiliated Hospital, Sun Yat-Sen University
Hepatic Encephalopathy (HE), MRI
7.0T Magnetic Resonance Imaging Study for Hepatic Encephalopathy
This clinical trial study aims to detect the imaging characteristics of patients with hepatic encephalopathy (HE) using 7-Tesla (7T) magnetic resonance imaging (MRI).
- Conditions
- Hepatic Encephalopathy (HE), MRI, fMRI Research
- Trial name
- NCT06923254
- Testing
- 7.0T MRI-Scan
- Where
- China
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Chinese PLA General Hospital
Acute Episode of Overt Hepatic Encephalopathy, Hepatic Encephalopathy
Phase 2B Efficacy/Safety of Ornithine Phenylacetate in Hospitalized Cirrhotic Patients With Hepatic Encephalopathy (STOP-HE)
The purpose of this study is to determine whether ornithine phenylacetate can speed recovery from an acute hepatic encephalopathy episode requiring hospitalization in cirrhotic patients.
- Trial name
- STOP-HE (NCT01966419)
- Testing
- ornithine phenylacetate
- Where
- 131 sites in United States, Australia and 15 more
- Volunteers
- 231 people
- Sponsor
- Ocera Therapeutics, Inc.
Hepatic Encephalopathy
Fecal Microbiota Transplantation (FMT) in the Management of Hepatic Encephalopathy (HE): a Pilot Study
The purpose of this study is to determine if FMT can reverse Hepatic Encephlopathy (HE) in cirrhotic patients who continue to have breakthrough episodes of HE despite maintenance therapy with lactulose and/or rifaximin or…
- Trial name
- NCT02255617
- Testing
- Fecal Microbiota Transplant
- Where
- Canada
- Volunteers
- 4 people
- Sponsor
- University of Alberta
Hepatic Encephalopathy
MNK-6105 for Patients With Cirrhosis and High Ammonia Levels Affecting Brain Function
This study is for patients with cirrhosis and hepatic encephalopathy who are in the hospital. This means they have a high ammonia level which is affecting their brain function.
- Trial name
- NCT04128462
- Testing
- MNK-6105, Standard of Care
- Sponsor
- Mallinckrodt
Hepatic Encephalopathy, Cirrhosis, Liver
Prevention of Post-TIPS Hepatic Encephalopathy by Administration of Rifaximin and Lactulose
Rationale: Hepatic encephalopathy (HE) is a major and common complication in patients with liver cirrhosis. HE can be classified in the extensive range of neurocognitive deterioration as minimal HE (MHE), covert HE (grade I), or…
- Conditions
- Hepatic Encephalopathy, Cirrhosis, Liver, Portal Hypertension, Liver Diseases
- Trial name
- PEARL (NCT04073290)
- Testing
- Rifaximin 550 milligram Oral Tablet [XIFAXAN], Lactulose 667 milligram/milliliter Oral Solution
- Where
- 6 sites in Belgium, Netherlands
- Volunteers
- 238 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Hepatic Encephalopathy, Liver Cirrhosis
Prediction of Post-TIPS Hepatic Encephalopathy in Patients With Liver Cirrhosis
Prediction of hepatic encephalopathy after insertion of a transjugular intrahepatic portosystemic stent shunt (post-TIPS HE) are critical for patient selection prior to TIPS insertion, and a currently unmet, clinically highly…
- Trial name
- NCT05466669
- Where
- 2 sites in Germany
- Volunteers
- 83 people
- Sponsor
- Johannes Gutenberg University Mainz
Cirrhosis, Refractory Ascites
Personalized Nutritional Intervention in Patients Undergoing TIPS Insertion for Refractory Ascites to Prevent Overt Hepatic Encephalopathy
This study will evaluate whether a nutritional intervention is better than another to reduce the incidence of overt hepatic encephalopathy in patients undergoing TIPS insertion for refractory ascites.
- Conditions
- Cirrhosis, Refractory Ascites, TIPS Insertion
- Trial name
- SUPPRESS-HE (NCT07634237)
- Testing
- High Energy and High Protein Diet 1, High Energy and High Protein Diet 2
- Where
- Canada
- Volunteers
- 50 people
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
Hepatic Encephalopathy, HE
Hepatic Encephalopathy: Lactulose or Polyethylene Glycol (H.E.L.P.)
The purpose of this study is to evaluate whether the use of polyethylene glycol is superior and more safe in treating hepatic encephalopathy compared to lactulose and also to determine if treatment with polyethylene glycol will…
- Conditions
- Hepatic Encephalopathy, HE, Cirrhosis, Altered Mental Status
- Trial name
- HELP (NCT01923376)
- Testing
- Lactulose, Polyethylene Glycol 3350
- Where
- United States
- Sponsor
- New York Presbyterian Brooklyn Methodist Hospital
Hepatic Encephalopathy
Speech in Hepatic Encephalopathy (HE)
This is an observational study that will test the clinical significance of speech features in patients with cirrhosis. It aims to assess if speech is associated with cognitive function at baseline, if speech predicts changes in…
- Trial name
- NCT05425316
- Testing
- Home Recordings, In-patient Recordings, Same-Day Study Visit - Regular Appointment
- Where
- United States
- Volunteers
- 251 people
- Sponsor
- University of Michigan